December 18, 2024 09:58 AM ESTUpdated 02:12 PM
People
Startups
Cell/Gene Tx

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Kyle LaHucik

Senior Reporter

Ring Ther­a­peu­tics, a start­up look­ing to ad­vance a new type of virus to de­liv­er gene ther­a­pies, has let go “just un­der 50%” of its work­force …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Tessera gets up to $50M from the Gates Foun­da­tion; Tvar­di’s re­verse merg­er

SiteOne Ther­a­peu­tics, a pain biotech that's part­nered with Ver­tex, nabs $100M

A service from the Financial Times